← Back to Clinical Trials
Recruiting NCT06879834

Assessing of Artificial Intelligence-based Software Platform for Diabetic Retinopathy Screening

Trial Parameters

Condition Diabetic Retinopathy
Sponsor The Filatov Institute of Eye Diseases and Tissue Therapy
Study Type OBSERVATIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2024-11-02
Completion 2025-08
Interventions
taking fundus photos using non-mydriatic fundus camera

Brief Summary

To examine the potential for the detection of diabetic retinopathy (DR) using the artificial intelligence (AI)-based software platform Retina-AI.

Eligibility Criteria

Inclusion Criteria: 1. Documented diagnosis of diabetes mellitus by definition. 2. Understanding of the Study and willingness and ability to sign informed consent 3. Patient age 18 or above 4. Diagnostic for diabetes: 4a) Type 1 diabetes of a lest 5 years of evolution; or 4b) Type 2 diabetes Exclusion Criteria: -1. Patients under 18 years of age; 2. Failure to give informed consent; 3. Presence of retinal diseases - acquired disease: age-related macular degeneration (AMD), occlusion of retinal vessels (ORV), etc.; birth defects: coloboma of choroid or optic nerve disc, etc.; hereditary diseases: retinitis pigmentosa, angioid streaks of the retina, etc. 4\. A patient who has already undergone treatment (surgery, laser, etc.) for any disease of the retina: age-related macular degeneration (AMD), retinal vascular occlusion (ARV), etc. These patients should be excluded or allocated to a separate group.

Related Trials